Gonadotropin-releasing hormone analogs in the treatment of endometriomas

article OA: closed CC0 ⤵ 20 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by gemini-2.5-flash-lite, 2026-06-07

This paper reviews the use of gonadotropin-releasing hormone analogs for treating endometriomas, exploring their efficacy and potential side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A limited number of small studies have assessed the efficacy of gonadotropin-releasing hormone agonists in the treatment of ovarian endometriomas. Most of these trials have not used quantitative measurements to evaluate the effects of therapy on disease resolution. The results available thus far suggest that nafarelin, buserelin, and histrelin offer modest degrees of efficacy, similar to that of danazol, in the management of patients with ovarian endometriotic cysts. Gonadotropin-releasing hormone agonists appear to be most efficacious when endometriomas are less than 1 cm in size.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Gonadotropin-Releasing Hormone Buserelin Danazol Danazol Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Nafarelin

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (8)

Cited by (20)

Source provenance

europepmc
last seen: 2026-09-06T09:34:12.023084+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:10.587122+00:00
License: CC0 · commercial use OK